<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39509140</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2578-5745</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>07</Day></PubDate></JournalIssue><Title>ACR open rheumatology</Title><ISOAbbreviation>ACR Open Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Comprehensive Enteroviral Serology Links Infection and Anti-Melanoma Differentiation-Associated Protein 5 Dermatomyositis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/acr2.11752</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Idiopathic inflammatory myopathies (IIMs) are a group of heterogeneous, systemic autoimmune diseases characterized by specific clinical features and, frequently, skeletal muscle inflammation. Specific subtypes of IIMs can be characterized by myositis-specific autoantibodies and are associated with distinct clinical phenotypes. Here, we focus on anti-melanoma differentiation-associated protein 5 (MDA5)-positive myositis and anti-signal recognition particle (SRP)-positive myositis, both of which exhibit seasonality but lack known environmental triggers.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We employed Phage ImmunoPrecipitation Sequencing to profile serum antibodies against the human proteome, the human virome, and a comprehensive enterovirus library. We analyzed sera from 57 patients with anti-MDA5 autoantibodies and 57 patients with anti-SRP autoantibodies, as well as 57 healthy controls. All groups were matched for age, sex, and race.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our autoantibody profiling results define specific immunogenic regions within the MDA5 and SRP autoantigens. We also discovered that in MDA5 sera, versus SRP sera, there was an elevated antibody response to the viral capsid protein 1 (VP1) of enterovirus B, which was accompanied by a decreased antibody response to rhinovirus A.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Considering the role of MDA5 as a sensor of picornaviral infections and a mediator of inflammatory signaling, our data suggest a novel etiologic link between enterovirus infection and anti-MDA5 dermatomyositis.</AbstractText><CopyrightInformation>© 2024 The Author(s). ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jayaraman</LastName><ForeName>Sahana</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3413-2530</Identifier><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiniakou</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-4749-870X</Identifier></Author><Author ValidYN="Y"><LastName>Morgenlander</LastName><ForeName>William R</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Na</LastName><ForeName>Miso</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0000-3700-859X</Identifier><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christopher-Stine</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-7150-7306</Identifier><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larman</LastName><ForeName>H Benjamin</ForeName><Initials>HB</Initials><Identifier Source="ORCID">0000-0001-7863-196X</Identifier><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08-AR0777032</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Peter and Carmen Lucia Buck Foundation</Agency><Country /></Grant><Grant><Agency>Jerome L. Greene Foundation</Agency><Country /></Grant><Grant><Agency>Jennifer Leonard Discovery Fund</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACR Open Rheumatol</MedlineTA><NlmUniqueID>101740025</NlmUniqueID><ISSNLinking>2578-5745</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>13</Day><Hour>13</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>13</Day><Hour>13</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>7</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39509140</ArticleId><ArticleId IdType="doi">10.1002/acr2.11752</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol 2018;14(5):290–302.</Citation></Reference><Reference><Citation>Lundberg IE, de Visser M, Werth VP. Classification of myositis. Nat Rev Rheumatol 2018;14(5):269–278.</Citation></Reference><Reference><Citation>Mariampillai K, Granger B, Amelin D, et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis‐specific autoantibodies. JAMA Neurol 2018;75(12):1528–1537.</Citation></Reference><Reference><Citation>Miller FW, Lamb JA, Schmidt J, et al. Risk factors and disease mechanisms in myositis. Nat Rev Rheumatol 2018;14(5):255–268.</Citation></Reference><Reference><Citation>Hosono Y, Nakashima R, Imura Y, et al. SAT0223 the onsets of myositis with myositis‐specific autoantibodies (MSAS) are associated with the seasons. Ann Rheum Dis 2013;72(suppl 3):A656–A656.</Citation></Reference><Reference><Citation>Nishina N, Sato S, Masui K, et al. Seasonal and residential clustering at disease onset of anti‐MDA5‐associated interstitial lung disease. RMD Open 2020;6(2):e001202.</Citation></Reference><Reference><Citation>Toquet S, Granger B, Uzunhan Y, et al. The seasonality of dermatomyositis associated with anti‐MDA5 antibody: an argument for a respiratory viral trigger. Autoimmun Rev 2021;20(4):102788.</Citation></Reference><Reference><Citation>So H, So J, Lam TT, et al. Seasonal effect on disease onset and presentation in anti‐MDA5 positive dermatomyositis. Front Med (Lausanne) 2022;9:837024.</Citation></Reference><Reference><Citation>Muro Y, Sugiura K, Hoshino K, et al. Epidemiologic study of clinically amyopathic dermatomyositis and anti‐melanoma differentiation‐associated gene 5 antibodies in central Japan. Arthritis Res Ther 2011;13(6):R214.</Citation></Reference><Reference><Citation>Miller T, Al‐Lozi MT, Lopate G, et al. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002;73(4):420–428.</Citation></Reference><Reference><Citation>Leff RL, Burgess SH, Miller FW, et al. Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti‐Jo‐1 and anti‐signal recognition particle autoantibodies. Arthritis Rheum 1991;34(11):1391–1396.</Citation></Reference><Reference><Citation>Mohan D, Wansley DL, Sie BM, et al. PhIP‐Seq characterization of serum antibodies using oligonucleotide‐encoded peptidomes. Nat Protoc 2018;13(9):1958–1978.</Citation></Reference><Reference><Citation>Nombel A, Fabien N, Coutant F. Dermatomyositis with anti‐MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol 2021;12:773352.</Citation></Reference><Reference><Citation>Misra AK, Wong NL, Healey TT, et al. Interstitial lung disease is a dominant feature in patients with circulating myositis‐specific antibodies. BMC Pulm Med 2021;21(1):370.</Citation></Reference><Reference><Citation>Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM‐140): a retrospective study. J Am Acad Dermatol 2011;65(1):25–34.</Citation></Reference><Reference><Citation>Kurtzman DJ, Vleugels RA. Anti‐melanoma differentiation‐associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol 2018;78(4):776–785.</Citation></Reference><Reference><Citation>Qiu R, Wang Z, Wei X, et al. The pathogenesis of anti‐signal recognition particle necrotizing myopathy: a review. Biomed Pharmacother 2022;156:113936.</Citation></Reference><Reference><Citation>Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990;33(9):1361–1370.</Citation></Reference><Reference><Citation>Rönnelid J, Barbasso Helmers S, Storfors H, et al. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev 2009;9(1):58–61.</Citation></Reference><Reference><Citation>Meyer A, Meyer N, Schaeffer M, et al. Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford) 2015;54(1):50–63.</Citation></Reference><Reference><Citation>Watanabe Y, Uruha A, Suzuki S, et al. Clinical features and prognosis in anti‐SRP and anti‐HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry 2016;87(10):1038–1044.</Citation></Reference><Reference><Citation>Hengstman GJ, ter Laak HJ, Vree Egberts WT, et al. Anti‐signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006;65(12):1635–1638.</Citation></Reference><Reference><Citation>Ge Y, Yang H, Xiao X, et al. Interstitial lung disease is not rare in immune‐mediated necrotizing myopathy with anti‐signal recognition particle antibodies. BMC Pulm Med 2022;22(1):14.</Citation></Reference><Reference><Citation>Dias Junior AG, Sampaio NG, Rehwinkel J. A balancing act: MDA5 in antiviral immunity and autoinflammation. Trends Microbiol 2019;27(1):75–85.</Citation></Reference><Reference><Citation>Suzuki S, Hayashi YK, Kuwana M, et al. Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. Arch Neurol 2012;69(6):728–732.</Citation></Reference><Reference><Citation>Iriki J, Yamamoto K, Senju H, et al. Influenza A (H3N2) infection followed by anti‐signal recognition particle antibody‐positive necrotizing myopathy: a case report. IJID 2021;103:P33–P36.</Citation></Reference><Reference><Citation>Suzuki I, Nakao R, Unai Y, et al. A case of anti‐SRP antibody‐positive immune‐mediated necrotizing myopathy triggered by human parvovirus B19 infection. Rinsho Shinkeigaku 2022;62(5):363–368.</Citation></Reference><Reference><Citation>Larman HB, Laserson U, Querol L, et al. PhIP‐Seq characterization of autoantibodies from patients with multiple sclerosis, type 1 diabetes and rheumatoid arthritis. J Autoimmun 2013;43:1–9.</Citation></Reference><Reference><Citation>Xu GJ, Kula T, Xu Q, et al. Comprehensive serological profiling of human populations using a synthetic human virome. Science 2015;348(6239):aaa0698.</Citation></Reference><Reference><Citation>Larman HB, Zhao Z, Laserson U, et al. Autoantigen discovery with a synthetic human peptidome. Nat Biotechnol 2011;29(6):535–541.</Citation></Reference><Reference><Citation>Monaco DR, Sie BM, Nirschl TR, et al. Profiling serum antibodies with a pan allergen phage library identifies key wheat allergy epitopes. Nat Commun 2021;12(379):1–10.</Citation></Reference><Reference><Citation>Angkeow JW, Monaco DR, Chen A, et al. Phage display of environmental protein toxins and virulence factors reveals the prevalence, persistence, and genetics of antibody responses. Immunity 2022;55(6):1051–1066.</Citation></Reference><Reference><Citation>Bohan, A., &amp; Peter, J. B. (1975). Polymyositis and Dermatomyositis. N Engl J Med 292(7):344–347. https://doi.org/10.1056/nejm197502132920706</Citation></Reference><Reference><Citation>Bohan, A., &amp; Peter, J. B. (1975). Polymyositis and Dermatomyositis. N Engl J Med 292(8):403–407. https://doi.org/10.1056/nejm197502202920807</Citation></Reference><Reference><Citation>Xu GJ, Shah AA, Li MZ, Xu Q, Rosen A, Casciola‐Rosen L, Elledge SJ. Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer. Proc Natl Acad Sci U S A. 2016;113(47):E7526–E7534. doi:10.1073/pnas.1615990113</Citation></Reference><Reference><Citation>Robinson MD, McCarthy DJ, Smyth GK, et al. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010;26(1):139–140.</Citation></Reference><Reference><Citation>Morgenlander W, Larman HB. GitHub ‐ wmorgen1/ARscore. March 8, 2023. Accessed May 2, 2023. https://github.com/wmorgen1/ARscore</Citation></Reference><Reference><Citation>Morgenlander WR, Chia WN, Parra B, et al. Precision arbovirus serology with a pan‐arbovirus peptidome. Nat Commun. 2024;15(1):5833. doi:10.1038/s41467‐024‐49461‐0</Citation></Reference><Reference><Citation>Monaco DR, Kottapalli SV, Breitwieser FP, et al. Deconvoluting virome‐wide antibody epitope reactivity profiles. EBioMedicine 2022;75:103747.</Citation></Reference><Reference><Citation>Sie B. GitHub ‐ brandonsie/phipcc: Case‐control reports for PhIP‐Seq. April 29, 2019. Accessed June 10, 2023. https://github.com/brandonsie/phipcc</Citation></Reference><Reference><Citation>Na M. A Novel Pipeline for Library Design and Deconvolution of Genus‐Wide Viral Epitope Reactivity Profiling. Dissertation. Johns Hopkins University; 2022.</Citation></Reference><Reference><Citation>Matsuda KM, Yoshizaki A, Kuzumi A, et al. Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti‐melanoma differentiation‐associated gene 5 antibody‐positive dermatomyositis. J Dermatol 2020;47(5):483–489.</Citation></Reference><Reference><Citation>Huang L, Zhu W, Ye Y, et al. Association of cytomegalovirus infection with anti‐MDA5 antibody‐positive dermatomyositis: a prospective cohort study. Front Med (Lausanne) 2021;8:740154.</Citation></Reference><Reference><Citation>Tonutti A, Motta F, Ceribelli A, et al. Anti‐MDA5 antibody linking COVID‐19, type I interferon, and autoimmunity: a case report and systematic literature review. Front Immunol 2022;13:937667.</Citation></Reference><Reference><Citation>Gonzalez D, Gupta L, Murthy V, et al. Anti‐MDA5 dermatomyositis after COVID‐19 vaccination: a case‐based review. Rheumatol Int 2022;42(9):1629–1641.</Citation></Reference><Reference><Citation>Mo Y, Ye Y, Peng L, et al. The central helicase domain holds the major conformational epitopes of melanoma differentiation–associated gene 5 autoantibodies. Rheumatology 2024;63(5):1456–1465.</Citation></Reference><Reference><Citation>Yamaguchi K, Poland P, Bijoy George T, et al. Correlation between B‐cell epitope profile and clinical features of anti‐MDA5 antibody‐positive dermatomyositis. Rheumatology 2024;63(7):2016–2023.</Citation></Reference><Reference><Citation>Aggarwal R, Oddis CV, Goudeau D, et al. Anti‐signal recognition particle autoantibody ELISA validation and clinical associations. Rheumatology (Oxford) 2015;54(7):1194–1199.</Citation></Reference><Reference><Citation>Yamaguchi K, Yamaguchi A, Kashiwagi C, et al. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti‐MDA5 autoantibodies with or without myositis‐associated autoantibodies. Respir Med 2018;140:1–5.</Citation></Reference><Reference><Citation>Sabbagh S, Pinal‐Fernandez I, Kishi T, et al; Childhood Myositis Heterogeneity Collaborative Study Group. Anti‐Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis 2019;78(7):988–995.</Citation></Reference><Reference><Citation>Huang K, Vinik O, Shojania K, et al. Clinical spectrum and therapeutics in Canadian patients with anti‐melanoma differentiation‐associated gene 5 (MDA5)‐positive dermatomyositis: a case‐based review. Rheumatol Int 2019;39(11):1971–1981.</Citation></Reference><Reference><Citation>Hall JC, Casciola‐Rosen L, Samedy LA, et al. Anti‐MDA5‐associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) 2013;65(8):1307.</Citation></Reference><Reference><Citation>Hosono Y, Nakashima R, Serada S, et al. Splicing factor proline/glutamine‐rich is a novel autoantigen of dermatomyositis and associated with anti‐melanoma differentiation‐associated gene 5 antibody. J Autoimmun 2017;77:116–122.</Citation></Reference><Reference><Citation>Yuan T, Mohan D, Laserson U, et al. Improved analysis of Phage ImmunoPrecipitation Sequencing (PhIP‐Seq) data using a Z‐score algorithm. bioRxiv. Published online April 26, 2018. doi: 10.1101/285916</Citation></Reference><Reference><Citation>Yamamoto AM, Gajdos P, Eymard B, et al. Anti‐titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol 2001;58(6):885–890.</Citation></Reference><Reference><Citation>Uhlén M, Fagerberg L, Hallström BM, et al. Proteomics. Tissue‐based map of the human proteome. Science 2015;347(6220):1260419.</Citation></Reference><Reference><Citation>The Human Protein Atlas. November 2016. Accessed May 2, 2023. https://www.proteinatlas.org/</Citation></Reference><Reference><Citation>Pons‐Salort M, Parker EP, Grassly NC. The epidemiology of non‐polio enteroviruses: recent advances and outstanding questions. Curr Opin Infect Dis 2015;28(5):479–487.</Citation></Reference><Reference><Citation>Pons‐Salort M, Oberste MS, Pallansch MA, et al. The seasonality of nonpolio enteroviruses in the United States: patterns and drivers. Proc Natl Acad Sci USA 2018;115(12):3078–3083.</Citation></Reference><Reference><Citation>Lincez PJ, Shanina I, Horwitz MS. Changes in MDA5 and TLR3 sensing of the same diabetogenic virus result in different autoimmune disease outcomes. Front Immunol 2021;12:751341.</Citation></Reference><Reference><Citation>Pollack A, Kontorovich AR, Fuster V, et al. Viral myocarditis–diagnosis, treatment options, and current controversies. Nat Rev Cardiol 2015;12(11):670–680.</Citation></Reference><Reference><Citation>Tschöpe C, Ammirati E, Bozkurt B, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol 2021;18(3):169–193.</Citation></Reference><Reference><Citation>Zhang C, Zhang X, Dai W, et al. A mouse model of enterovirus D68 infection for assessment of the efficacy of inactivated vaccine. Viruses 2018;10(2):58.</Citation></Reference><Reference><Citation>Sun S, Bian L, Gao F, et al. A neonatal mouse model of enterovirus D68 infection induces both interstitial pneumonia and acute flaccid myelitis. Antiviral Res 2019;161:108–115.</Citation></Reference><Reference><Citation>Kochi Y, Kamatani Y, Kondo Y, et al. Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Ann Rheum Dis 2018;77(4):602–611.</Citation></Reference><Reference><Citation>Theisen DJ, Davidson JT IV, Briseño CG, et al. WDFY4 is required for cross‐presentation in response to viral and tumor antigens. Science 2018;362(6415):694–699.</Citation></Reference><Reference><Citation>Berger M, Hsieh CY, Bakele M, et al. Neutrophils express distinct RNA receptors in a non‐canonical way. J Biol Chem 2012;287(23):19409–19417.</Citation></Reference><Reference><Citation>Pinal‐Fernandez I, Muñoz‐Braceras S, Casal‐Dominguez M, Pak K, et al. Pathogenic autoantibody internalization in myositis. Ann Rheum Dis. 2024:ard‐2024‐225773. doi: 10.1136/ard‐2024‐225773</Citation></Reference><Reference><Citation>Ye Y, Chen Z, Jiang S, et al. Single‐cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications. Nat Commun 2022;13(1):6458.</Citation></Reference><Reference><Citation>Qian J, Li R, Chen Z, et al. Type I interferon score is associated with the severity and poor prognosis in anti‐MDA5 antibody‐positive dermatomyositis patients. Front Immunol 2023;14:1151695.</Citation></Reference><Reference><Citation>Wu B, Peisley A, Richards C, et al. Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5. Cell 2013;152(1–2):276–289.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>